EMSAM
LOE Approachingselegiline
NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
EMSAM (selegiline) is monoamine oxidase inhibitors [moa]. First approved in 2006.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMSAM is a transdermal extended-release film formulation of selegiline, a monoamine oxidase inhibitor (MAOI) approved in February 2006 for major depressive disorder (MDD). It works by inhibiting monoamine oxidase enzymes, thereby increasing levels of serotonin, norepinephrine, and dopamine in the central nervous system. The transdermal delivery route provides steady-state dosing and may offer improved tolerability compared to oral MAOI formulations, positioning it as a treatment option for patients with MDD who have not responded to other antidepressants.
$0.0BPart D
Mechanism of Action
Monoamine Oxidase Inhibitors
Pharmacologic Class:
Monoamine Oxidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Started Mar 2007
77 enrolled
Parkinson's Disease
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
127 enrolled
Cognition DisordersHIV Infections
Career Relevance
EMSAM, as a legacy product in LOE stage, creates limited career opportunities focused primarily on market defense and managed decline roles such as brand managers overseeing generic transition, sales representatives maintaining existing prescriber relationships, and MSLs educating healthcare providers on appropriate patient selection for treatment-resistant MDD. Currently, zero open roles are linked to this product, reflecting its mature, stable market position. Professionals working on EMSAM require expertise in MAOI pharmacology, managed care contracting, and transition planning for generic competition.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.